

Tazverik™ (Tazemetostat) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Pharmacy billing (NDC: _____)

Dose: _____ Regimen: _____ Start Date: _____

Billing Provider Information

Pharmacy NPI: _____ Pharmacy Name: _____

Pharmacy Phone: _____ Pharmacy Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria**For Initial Authorization:**

1. Please indicate the diagnosis and information:

 Epithelioid Sarcoma

A. Is disease metastatic or locally advanced? Yes ___ No ___

B. Is member eligible for complete resection? Yes ___ No ___

 Follicular Lymphoma (FL)

A. Is disease relapsed or refractory? Yes ___ No ___

B. EZH2 detected mutation? Yes ___ No ___

C. Has member received at least 2 lines of therapy? Yes ___ No ___

D. Will tazemetostat be used as subsequent therapy where there are no satisfactory alternative treatment options? Yes ___ No ___

 If answer is none of the above, please indicate diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does patient have any evidence of progressive disease while on tazemetostat therapy? Yes ___ No ___

3. Has the member experienced any adverse drug reactions related to tazemetostat therapy? Yes ___ No ___

If yes, please specify adverse reactions: _____

Additional Information: _____

Prescriber Signature: _____ **Date:** _____**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.***Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.***PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:**University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization UnitFax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4**CONFIDENTIALITY NOTICE***This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*